For: | Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15(4): 724-734 [PMID: 38680706 DOI: 10.4239/wjd.v15.i4.724] |
---|---|
URL: | https://www.wjgnet.com/1948-9358/full/v15/i4/724.htm |
Number | Citing Articles |
1 |
Saeed Mohammadi, Ahmed Al-Harrasi. Macrophage modulation with dipeptidyl peptidase-4 inhibitors: A new frontier for treating diabetic cardiomyopathy?. World Journal of Diabetes 2024; 15(9): 1847-1852 doi: 10.4239/wjd.v15.i9.1847
Abstract(117) |
Core Tip(97) |
Full Article(HTML)(453)
|
Full Article with Cover (PDF)-1354K(14)
|
Full Article (Word)-249K(0)
|
Audio-895K(0)
|
Peer-Review Report-170K(7)
|
Answering Reviewers-54K(18)
|
Full Article (PDF)-986K(33)
|
Full Article (XML)-69K(9)
|
Times Cited (0)
|
Total Visits (983)
|
Open
|
2 |
Jing Guo, Yi Cao, Qing-Yuan Wu, Lu-Sha Cen. Potential mechanism of teneligliptin in the treatment of diabetic cardiomyopathy. World Journal of Diabetes 2024; 15(10): 2002-2005 doi: 10.4239/wjd.v15.i10.2002
|
3 |
Cornelius James Fernandez, Sahana Shetty, Joseph M Pappachan. Diabetic cardiomyopathy: Emerging therapeutic options. World Journal of Diabetes 2024; 15(8): 1677-1682 doi: 10.4239/wjd.v15.i8.1677
|
4 |
Ashraf Al Madhoun. Teneligliptin: A potential therapeutic approach for diabetic cardiomyopathy. World Journal of Diabetes 2024; 15(8): 1654-1658 doi: 10.4239/wjd.v15.i8.1654
|
5 |
Lu Cai, Yi Tan, Md Shahidul Islam, Michael Horowitz, Kupper A Wintergerst. Diabetic cardiomyopathy: Importance of direct evidence to support the roles of NOD-like receptor protein 3 inflammasome and pyroptosis. World Journal of Diabetes 2024; 15(8): 1659-1662 doi: 10.4239/wjd.v15.i8.1659
|